ARTICLES. Patients and Methods
|
|
- Nathan Cobb
- 5 years ago
- Views:
Transcription
1 ARTICLES Radotherapy Alone Versus Combned Chemotherapy and Radotherapy n Nonresectable Non-Small-Cell Lung Cancer: Frst Analyss of a Randomzed Tral n Patents Therry Le Chevaler* Rodrgo Arragada, Elzabeth Quox, Perre Ruffle, Mchel Martn, Mchele Tarayre, Mare-Jose Lacombe-Terrer, Jean-Yves Doullard, Agnes Laplanche We report the results observed n a large, randomzed study that compared the effects of radotherapy alone (the standard therapy) wth those of a combnaton of radotherapy and chemotherapy n nonresectable squamous cell and large-cell lung carcnoma. The radaton dose was Gy n each group, and chemotherapy ncluded vndesne, cyclophosphamde, csplatn, and lomustne. In ths study, patents receved radotherapy alone (group A), and patents receved the combned treatment (group B). The 2- year survval rate was 4% n group A and 2% n group B (P =.0). The dstant metastass rate was sgnfcantly lower n group B (P<.00). Local control was poor n both groups (% and %, respectvely) and remaned the major problem. [J Natl Cancer Inst :4-42,99] Non-small-cell lung cancer accounts for 0% of lung cancers, the prmary cause of mortalty from malgnant dsease n western countres (/). Squamous cell carcnoma and large-cell carcnoma represent approxmately % of non-small-cell lung cancer n France (2), and ther curatve treatment s surgery. In most cases, however, the dsease s noperable at the tme of presentaton because of ether metastass or locally advanced tumor that s nonresectable. Of patents wth locally advanced non-small-cell lung cancer, % to 0% wll de from ntrathoracc dsease, wth or wthout dstant metastases (,4). The medan survval of such patents s less than months wthout treatment (). Wth radcal radotherapy, a complete radologc response can be obtaned n % to 0% of these cases and an objectve radologc response n 40% to % of cases (,). Even n the case of apparent local control, however, long-term survval remans dsappontng because of the hgh rate of dstant metastases (). Ths stuaton led us n 90 to conduct a phase II study combnng radcal radotherapy and a four-drug chemotherapy regmen comprsng vndesne, csplatn, lomustne, and cyclophosphamde (VCPC). We observed a 42% objectve response rate after ntal chemotherapy and a 4.% complete remsson rate after combned-modalty treatment, wth a medan survval of.9 months (9). On the bass of these results, we desgned a phase III study comparng such a combned schedule wth radotherapy alone gven at the same doses. We report here the frst analyss of ths large multcenter randomzed tral that ncluded patents. Patents and Methods Patents entered n ths study were prevously untreated and had hstologcally proven squamous cell or large-cell carcnoma of the lung. Patents wth adenocarcnoma were excluded because of the dffculty of determnng the orgn of the prmary tumor n a large subset of patents (). Receved September,990; revsed December 4,990; accepted January,99. Supported n part by grant IGR CR 9 D9 from the Insttut Gustave-Roussy. T. Le Chevaler, R. Arragada, P. Ruffe, M. Tarayre, M.-J. Lacombe-Terrer, A. Laplanche, Insttut Gustave-Roussy, Vllejuf, France. E. Quox, Centre Hosptaler Regonal, Strasbourg, France. P. Ruffe, M. Martn, Centre Hosptaler Intercommunal, Crttel, France. J.-Y. Doullard, Centre Renf Gauducheau, Nantes, France. We thank Mrs Lorna Sant-Ange and Mrs Catherne Loge for ther help n preparng ths manuscrpt. *Corrcspondence to: Dr Therry Le Chevaler, Dfpartement de Mddecne, Insttut Gustave-Roussy, 9400 Vllejuf, France. Downloaded from at Pennsylvana State Unversty on May, 20 Vol., No., March 20, 99 ARTICLES 4
2 All patents were judged to have nonresectable dsease but to be free of metastass after physcal examnaton and bronchoscopc, radologc, and nuclear dagnostc study. Elgblty crtera were as follows: age less than or equal to 0 years, Karnofsky performance status greater than 0%, measurable or evaluable dsease, no pror chemotherapy or radaton therapy, no hstory of malgnant dsease (except basal cell skn carcnoma), no hematologc, cardac, renal, or lver abnormaltes contrandcatng the combned modalty therapy, no esophageal or chest-wall nvolvement, no pleural effuson except for that n patents wth bopsy-proven negatve hstology, and no superor vena cava syndrome requrng urgent radaton therapy. All patents underwent the followng nvestgatons: chest x ray and fberoptc bronchoscopy; bone scan, bran scntgraphy, or computerzed axal tomographc (CAT) scan; and lver CAT scan or ultrasonography. Dsease had to be lmted to one hemthorax, the medastnum, and supraclavcular nodes, provded all nodes could be ncluded n the same radotherapy felds as the prmary tumor. Each patent who fulflled ncluson crtera was randomly allocated to one of two groups wthn 2 weeks of complete assessment. Study Desgn Patents were randomly allocated to one of two regmens (Fg ). Regmen A (group A patents) conssted of radotherapy alone gven to a volume ncludng prmary tumor, medastnum, and blateral supraclavcular nodes. A total radaton dose of Gy n 2 fractons gven durng a 4-day perod wth approprate spnal sheldng was prescrbed (). The sequental scheme of the technque was as follows: (a) Two large opposed anteroposteror/posteroanteror complex-shaped beams rradated the whole target volume, ncludng tumor volume and homolateral hlar, medastnal, and supraclavcular lymph nodes, wth a free margn of to. cm. The dose delvered wth ths frst-beam arrangement was lmted to 40 Gy n fractons gven durng a perod of 2 days. (b) Two opposed lateral beams rradated the target, ncludng the tumor and hlar and medastnal lymph nodes. The dose delvered wth ths second-beam arrangement was Gy n fractons gven durng a perod of days. (c) Two opposed oblque beams rradated the target, ncludng the tumor and homolateral hlar and medastnal lymph nodes. The dose delvered wth ths thrd-beam arrangement was Gy n 4 fractons gven durng a perod of days. Regmen B (group B patents) ncluded three monthly cycles of VCPC therapy: vndesne,. mg/m 2 on days and 2; lomustne, 0 mg/m 2 on day 2 and 2 mg/m 2 on day ; csplatn, 0 REGIMEN A: RADIOTHERAPY ALONE QY Fg. Desgn of the study. LOCALLY ADVANCED SQUAMOUSCELL OR LARGE CELL LUNQ CARCINOMA RANDOMIZATION REGIMEN B: VCPC + RADIOTHERAPY GY ±VCPC mg/m 2 on day 2; and cyclophosphamde, 200 mg/m 2 on days 2 through 4. Radographc, fberoptc, and hstologc examnatons were performed just before the thrd cycle to determne the response to ntal chemotherapy. All patents receved thoracc radotherapy dentcal to that of regmen A begnnng 2 to weeks after the thrd chemotherapy cycle. Three addtonal VCPC cycles were admnstered after completon of radotherapy to patents whose dsease had not progressed after ntal chemotherapy. Fnal assessments dentcal to those performed before randomzaton were performed months after completon of radotherapy to determne fnal response rates n both groups. Dose Adjustments n Regmen B If myelosuppresson was observed at the start of a new chemotherapy cycle, the course was delayed untl normal blood count recovery. If platelet count was less than 0 000/mm, lomustne was wthdrawn from the cycle. Response Crtera Complete remsson was ndcated by the complete dsappearance of all objectve tumor shown by chest x ray and no evdence of new dsease shown by optcal and hstologc examnaton durng fberoptc bronchoscopy. Partal remsson was ndcated by a decrease greater than or equal to 0% n the product of the two largest perpendcular dameters of radologcally measurable dsease, wth concurrent endoscopc verfcaton and no evdence of new dsease. Stable dsease was ndcated by no change shown by radologc and endoscopc examnaton and no evdence of new dsease. Progressve dsease was ndcated by radologc or endoscopc evdence of progresson or evdence of new dsease. Only patents n complete remsson were consdered as havng locally controlled dsease. Toxc Effects Toxc effects were evaluated accordng to World Health Organzaton crtera (2). Second-Lne Treatment Patents who faled after radotherapy alone were proposed for the VCPC regmen, any phase II study, or the best supportve care. Patents who dd not respond to the combned treatment could be ether ncluded n any phase II study or gven the best supportve care. Statstcal Methods The study was a multcenter controlled tral. Patents were randomly allocated to regmen groups at the Insttut Gustave- Roussy, and the treatment arm was allocated by means of a computer-generated lst balanced every four patents and stratfed by center. We estmated that a mnmum of patents per group would be needed to demonstrate a mnmum dfference of % n 2-year survval between the two groups, wth a type I error of % and a type II error of %. We compared the two groups of patents by usng the chsquare test, Student's / test, and Fsher's Exact Test. The Kaplan-Meer method () and the log-rank test (4) were used Downloaded from at Pennsylvana State Unversty on May, 20 4 Journal of the Natonal Cancer Insttute
3 for the estmaton and comparson of survval curves for all patents and of local control curves for complete responders. Results Patent and Treatment Characterstcs From June 9 to February 99, patents were entered from the cooperatng centers lsted n the "Appendx" secton. Seven centers entered 9% of the patents. Patent characterstcs are lsted n Table. The Internatonal Unon Aganst Cancer (UICC) 99 TNM classfcaton was used (). Of the patents wth cancers classfed T-T2/N0-N at the tme of ntal workup, had exploratve thoracotomes, and the other 2 patents had functonal contrandcatons to surgery. The remanng 20 patents could not have surgery because of tumor or lymph node extenson. Two patents wth chest wall nvolvement were nelgble for study. Only dstrbuton of genders dffered sgnfcantly between groups A and B (P<.0). Performance status was slghtly better n the combned arm (P =.0). No patent was lost to follow-up, and all are avalable for survval rate estmatons. The sldes made from specmens of 0 patents (%) have been revewed. Among these, the hstologc subtype of the car- Characterstc Males, % Mean age, y Pathology, % Squamous cell carcnoma Well-dfferentated Moderately dfferentated Poorly dfferentated Large-cell carcnoma TNM classfcaton, % Tl T2 T NO Nl N2 N MO Ml* Chest wall nvolvement, % Ste, % Lung Upper lobe Mddle lobe Lower lobe Man bronchus Carna Trachea Kamofsky ndex 20, % Abnormal carcnoembryonc antgen, % Table. Patent characterstcs Radotherapy alone. tchemotherapy + radotherapy. t Apples only to supraclavcular nodes. A* Group Bt cnoma could not be determned for cases, and the lung was consdered a lkely metastatc ste n 4 cases. Complance Regmen A ( patents). Twenty-nne patents (%) receved an ncomplete course of radotherapy. Of these, 4 patents dd not receve rradaton; 20 patents receved only the frst seres; and patents receved two seres, but at a total dose rangng from 42 to Gy. Regmen B ( patents). Seven patents dd not receve ntal chemotherapy because of refusal (2 patents), early death (2 patents), or protocol volatons ( patents). Ffteen patents receved only one cycle of chemotherapy because of refusal ( patents), toxc effects ( patents), death (4 patents), dsease progresson ( patents), or protocol volatons (2 patents). Twenty patents receved only two cycles because of refusal (4 patents), toxc effects (2 patents), death ( patent), dsease progresson ( patents), or protocol volatons (2 patents). When chemotherapy was admnstered, the planned dose was delvered except n the case of lomustne (0% of the total dose). Ffty-seven patents (2%) receved an ncomplete course of radotherapy. Of these, patents dd not receve radotherapy because of death ( patents), dsease progresson ( patents), refusal ( patents), protocol volatons (4 patents), or surgcal resectons (2 patents); 22 receved a total dose of less than Gy each because of dsease progresson. Of 94 patents for whom ntal response to chemotherapy ndcated three addtonal VCPC cycles after radotherapy, 0 patents receved three cycles, 4 patents receved two cycles, and patents receved one cycle; the other patents dd not receve addtonal chemotherapy because of refusal ( patents), death ( patents), toxc effects (4 patents), or dsease progresson ( patents). Fnally, fve patents n regmen B underwent operatons after the thrd chemotherapy cycle. Tumor Response to Intal Chemotherapy Data are avalable for response n 4 of the 9 patents who receved at least one chemotherapy cycle. Forty-fve (2%) had objectve responses determned by radologc and endoscopc examnatons after two cycles of chemotherapy. Seventy-two patents (44%) had responses (<0%) or stable dsease, and 4 patents (29%) experenced progresson of dsease to local or dstant stes. Fnal Assessment The mean delay between randomzaton and the fnal assessment was. months for regmen A and. months for regmen B. Regmen A ( patents wth follow-up). Complete remssons were observed n patents (20%), and partal remssons were observed n 2 patents (objectve response rate, %). Stable dsease was observed n patents, and progressve dsease was observed n patents. Regmen B ( patents wth follow-up). Complete remssons were observed n 2 patents (%), and partal remssons were observed n 2 patents (objectve response rate, %). Stable dsease was observed n 2 patents, and progressve dsease was observed n patents. Downloaded from at Pennsylvana State Unversty on May, 20 Vol., No., March 20, 99 ARTICLES 49
4 Survval Survval was calculated from the date of random allocaton of a patent to the date of death or last follow-up. The tme between randomzaton and the analyss ranged from to months; the mean follow-up tme for groups A and B was 40 months and 4 months, respectvely. Medan survval was months n group A and 2 months n group B. One hundred twenty-four patents n group A and 2 patents n group B ded of progressve dsease. Survval curves are shown n Fg 2. The survval rate was 4% at year, 4% at 2 years, and % at years for group A and 0%, 2%, and %, respectvely, for group B. A comparson of survval between the two arms by means of the logrank test yelded a P value of.0. The relatve rsk of death was.2 for the radotherapy arm compared wth that of the combned chemotherapy and radotherapy arm. Comparson of survval remaned statstcally nonsgnfcant when adjusted for center, performance status, and gender. Local Control Because local control was not the man goal of the study, the best local response was not determned. Local control at year was % for group A and % for group B. The local control curves of the complete responders n group A and the 2 complete responders n group B are shown n Fg ; there was no sgnfcant dfference between the two groups. Dstant Metastass Sxty-seven patents n group A and 4 patents n group B experenced metastass to dstant stes. The actuaral metastass rates are shown n Fg 4. The metastass rate was sgnfcantly lower n group B (f<.00). The relatve rsk of metastases was 2.0 n the radotherapy arm compared wth that of the combned chemotherapy and radotherapy arm. Ths dfference remans sgnfcant when adjusted for center, performance status, and gender. 0 0 Fg. Local control curves of complete responders n the two groups startng at the tme of fnal assessment. = radotherapy alone ( patents); = radotherapy + chemotherapy (2 patents) b) 0 2 T I-"'" Fg 4. Actuaral metastass rate n the two groups. = radotherapy + chemotherapy. I 4 months - = radotherapy alone; As shown n Table 2, the stes of frst metastases, consdered at any tme of follow-up, are not sgnfcantly dfferent between the two groups. Long-Term Survval Only patent ded among the 2 patents for whom survval exceeded 0 months. Ten patents are stll n complete remsson, and the condton of patent s stable, wth persstent dsease observed by endoscopy and mcroscopy, for 4 months wth no specfc treatment. Table 2. Frst ste of metastass wth respect to type of therapy Downloaded from at Pennsylvana State Unversty on May, Yx 2 \ r 4 months No. recevng therapy Ste of metastass Group A* Group Bf Pleura/pulmonary tssue Lver Bone Subcutaneous tssue Bran Lymph nodes Multple stes Other stes Fg 2. Overall survval curves n the two groups. = radotherapy + chemotherapy. - = radotherapy alone; Radotherapy alone. tchemotherapy + radotherapy. 420 Journal of the Natonal Cancer Insttute
5 Toxc Effects Toxc effects were prmarly hematologc abnormaltes and dgestve dsorders n the chemotherapy group. Grade III and IV toxc effects are lsted n Table. One patent experenced a grade IV neurologc toxc effect after the frst chemotherapy cycle, and chemotherapy was dscontnued. One patent experenced a grade V renal toxc effect after the second cycle of chemotherapy. Radaton-related toxc effects were observed n 2 of the patents who receved the frst course of radotherapy and n of the 20 patents who receved the second course of radotherapy. Toxc effects were mld to moderate n most cases, and the dscontnuaton of treatment was never necessary. Grade II through IV toxc effects are lsted n Table 4. Eght patents suffered treatment-related, ultmately fatal toxc effects. Of these, two patents developed pneumonts and one patent developed percardts n group A, and four patents developed aplasa and one patent experenced renal falure n group B. Dscusson Cycle Frst Second Thrd Fourth Ffth Sxth Table. Grade III or IV toxc effects after chemotherapy n Abnormal hemoglobn level 4 The therapeutc approach for locally advanced non-small-cell lung cancer has been wdely dscussed. Extensve lterature has reported the possblty of mprovng survval wth thoracc rradaton, and ths treatment can be consdered as standard therapy for ths type of presentaton n spte of a poor medan survval not exceedng to 2 months {,). The hgh ncdence of local relapses and/or dstant metastases, however, calls for systemc treatment {); therefore, t was es- No. of patents wth Thrombocytopena Neutropena 2 9 Table 4. Grade II through IV toxc effects of radotherapy Dgestve tract dsorders No. of patents Toxc effect Group A* Group Bt Esophagts Cutaneous dsorder Pneumonts Hematologc dsorder Dgestve tract dsorder Weght loss Fever Radotherapy alone. tchemotherapy + radotherapy II 9 I sental that the combnaton of these two modaltes be clearly evaluated. The ratonale for combnng radotherapy and chemotherapy n nonresectable non-small-cell lung cancer n the present tral was ) to mprove the local control rate by delverng radaton at adequate doses, e, Gy n. weeks, 2) not to exceed ths dose as well as to avod toxc effects on normal tssues n the thorax, and ) to decrease the dstant-metastass rate by actng on mcrometastases exstng at the tme of presentaton n more than 0% of cases (/). The four drugs selected were among the most effectve avalable at the tme of the desgn, and the doses employed permtted delvery of adequate radaton doses n a prelmnary phase II tral (9). In the present study, the chemotherapy regmen allowed an objectve regresson of the prmary tumor n 2% of the cases. Ths response rate s modest when compared wth results of recent phase II studes {-20), but t s assocated wth patents wth bulky dsease who were ncluded n a multcentrc study and receved fberoptc control examnatons and systematc bopses after two chemotherapy cycles. Treatment response was evaluated at a fxed tme months after completon of radotherapy; therefore, t was possble for a patent to experence a complete local response but very soon after exhbt dstant metastases. Furthermore, our defnton of local control was delberately restrctve. These factors may explan the low complete remsson rate observed at the tme of fnal assessment. Nevertheless, the -year local control rate s partcularly poor n both groups. These fgures are obvously dfferent from the "best response rate per patent" reported n most studes n whch mpact on survval s not clearly defned (2,22). The most dramatc effect observed n the present tral s the sgnfcant mpact of chemotherapy on the rate of dstant metastases. Ths fact s of crtcal mportance because t demonstrates that chemotherapy can sgnfcantly decrease the metastass rate n locally advanced dsease. Nevertheless, the dfference n overall survval was margnal and remaned below sgnfcance; the lack of local control (% and % at year) s the most probable explanaton of the results observed here. We emphasze that 40% of complete responders are long-term survvors. Sx other randomzed studes {2-2) that compared results of radotherapy alone and those of combned chemotherapy and radotherapy that ncluded more than 0 patents each have been reported and are lsted n Table. Only one study has demonstrated a sgnfcant beneft for survval n the combned modalty arm {2). An advantage was demonstrated, however, for the combned arm n fve of sx studes, as n our tral the largest conducted to date a moderate, although nonsgnfcant, beneft of a strategy that employed moderately actve chemotherapy regmens. Our results wll have a clear mpact on the followng future protocol desgns accordng to the new UICC classfcaton {29) that takes nto account two dfferent subsets of patents wth locally advanced non-small-cell lung cancer: ) Use of newer drugs {0Jl) and combnaton regmen wll probably be able to ncrease the complete response rate and therefore mprove the control of mcrometastases. Downloaded from at Pennsylvana State Unversty on May, 20 Vol., No., March 20, 99 ARTICLES 42
6 Table S. Randomzed studes comparng radotherapy (RT) alone wth combned radotherapy and chemotherapy (CT) n locally advanced non-small-cell lung cancer Reference No. (2) () (2) (2) (2) (2) Present study n 2 Dose RT, Gy 4 CT* Medan survval, mo: RT/RT+CT CAMP 2/ MACC / VDS 9/ VLB-CDDP 9/ ADM CAP VCPC (unresectable squamous cell lung carcnoma) 9/ / /2 -y survval, %: RT/RT+CT 4/4 / / 4/42 4/0 <.00 *CAMP = cyclophosphamde + doxorubcn + methotrexate + procarbazne; MACC = methotrexate + doxorubcn + lomustne + cyclophosphamde; VDS = vndesne; VLB-CDDP = vnblastne + csplatn; ADM = doxorubcn; CAP = cyclophosphamde + doxorubcn + csplatn; and VCPC = vndesne + cyclophosphamde + csplatn + lomustne. f = not sgnfcant. 2) Patents presentng wth margnally operable dsease (stage MA) can potentally beneft from preoperatve chemotherapy as suggested by many phase II studes (2-4). Randomzed trals able to defne adequately the subset of patents lkely to beneft from the effect of chemotherapy on both local and dstant dsease are urgently requred. ) Patents wth defntvely nonresectable tumor (most patents wth stage IIIB dsease) can be consdered for new combned-modalty strateges, ncludng multfractonated radotherapy () and concurrent chemotherapy and radotherapy (,), n an attempt to mprove local control. 4) Standard treatment of patents wth locally advanced, defntvely nonresectable non small-cell lung cancer remans manly pallatve, and radotherapy s probably the most cost-effectve and comfortable alternatve that can be proposed today. In concluson, treatment of locally advanced non-small-cell lung cancer remans controversal. The large mpact of chemotherapy on the metastass rate observed n the present study must be emphaszed, although the dsappontng local control rate does not afford a sgnfcant beneft for overall survval. The new stratfcaton of margnally operable or defntvely nonresectable tumors offers new therapeutc prospects, and recent strateges should therefore be adequately evaluated n each category. References (/) SILVERBERG E, LUBERA JA: Cancer statstcs, 9. CA :-22, 9 (2) Statstque des causes medcales de deces: 9-9. Pars: IEE and IERM () Cox JD, YESNER R, MIETLOWSKI W, ET AL: Influence of cell type on falure pattern after rradaton for locally advanced carcnoma of the lung. Cancer 44:94-9,99 (O MATTHEWS M, PICKREN J, KANHOUWA S: Who has occult metastass? Resdual tumor n patents undergong surgcal resectons for lung cancer. In Perspectves n Lung Cancer (Yohn DC, ed). Basel: Karger, 9, pp 9- () ZELEN M: Keynote address on bostatstcs and data retreval. Cancer Cbemother Rep 4:-42, 9 () Cox JD, KOMAKI R, BYHARDT RW: IS mmedate chest radotherapy oblgatory for any or all patents wth lmted-stage non-small cell carcnoma of the lung? Yes. Cancer Treat Rep :2-, 9 () PEREZ CA, STANLEY K, GRUNDAY G, ET AL: Impact of rradaton technque and tumor extent n tumor control and survval of patents wth unresectable non-oatcell carcnoma of the lung: Report by the Radaton Therapy Oncology Group. Cancer 0:9-99,92 () COHEN MH: IS mmedate radaton therapy ndcated for patents wth unresectable non-small-cell lung cancer? No. Cancer Treat Rep :-, 9 (9) LE CHEVALIER T, ARRIAGADA R. BALDEYROU P, ET AL: Combned chemotherapy (vndesne, lomustne, csplatn, and cyclophosphamde) and radcal radotherapy m noperable nonmetastatc squamous cell carcnoma of the lung. Cancer Treat Rep 9:49-42, 9 (0) LE CHEVAUER T, Cvrrxovc E, CAILLE P, ET AL: Early metastatc cancer of unknown prmary orgn at presentaton. A clncal study of 02 consecutve autopsed patents. Arch Intern Med 4:20-209, 9 (//) CHAVAUDRA J, ARRIAGADA R: Radotherapy plannng n lung cancer. The Gustave-Roussy Insttute approach. Cancer Treat Symp 2:-9, 9 (2) WORLD HEALTH ORGANIZATION: Handbook for reportng results of cancer treatment. WHO Publ No. 4, 99 () KAPLAN EL, MEIER P: Nonparametrc estmatons from ncomplete observatons. J Am StatAssoc :4-, 9 (4) PETO R, PIKE MC, ARMITAGE P, ET AL: Desgn and analyss of randomzed clncal trals requrng prolonged observatons of each patent. II. Analyss and examples. Br J Cancer : -9, 9 () HAEN HH, HIRSCH FR, RORTH M: Stagng and prognoss. In Lung Tumors (Hoogstraten B, Adds BJ, Hansen HH, et al, eds). Berln: Sprnger-Verlag, 9 () GRECO FA: Ratonale for chemotherapy for patents wth advanced nonsmall-cell lung cancer. Semn Oncol :92-9, 9 () GOLDSTRAW P: CT scannng n the preoperatve assessment of non-smallcell lung cancer. In Lung Cancer Basc and Clncal Aspects (Hansen HH, ed). Boston: Martnus-Njhoff, 9, pp -9 () BONOMI P: Bref overvew of combnaton chemotherapy n non-small-cell lung cancer. Semn Oncol :9-9,9 (9) BURKES R, GIBERG RF, SHEPHERD M, ET AL: Phase II plot program of neo-adjuvant chemotherapy for stage III (Tl-, N2, M0) unresectable nonsmall-cell lung cancer (CLC). Lung Cancer 4:A, 9 (20) GRALLA RJ, KRIS MG, POTANOVICH LM, ET AL: Enhancng the safety and effcacy of the MVP regmen (mtomycn + vnblastne + csplatn) n 0 patents wth noperable non-small-cell lung cancer. Proc ASCO :, 99 (2) CHOI NC, DOUCETTE JA: Improved survval of patents wth unresectable non-small-cell bronchogenc carcnoma by nnovated hgh-dose en-bloc radotherapeutc approach. Cancer 4:-9, 9 (22) SCHAAKE-KONING C, SCHUSTER-VlTTERHOEVE L, HART G, ET AL: PrOgnOStc factors of noperable localzed lung cancer treated by hgh dose radotherapy. Int J Radat Oncol Bol Phys 9:2-2, 9 (2) TROVO MG, VERONESI A, BORTOLUS R, ET AL: IS chemotherapy necessary n the management of unresectable non-metastatc non-small-cell lung cancer? In Treatment Modaltes n Lung Cancer (Arragada R, Le Chevaler T, eds). Basel: Karger, 9, pp 2- () MORTON RF, JETT JR, MAHER L, ET AL: Randomzed tral of thoracc radaton therapy wth or wthout chemotherapy for treatment of locally unresectable non-small-cell lung cancer. Proc ASCO abstract No. 2, 9 (2) JOHON DH, EINHORN LH, BIRCH R, ET AL: IS mmedate thoracc radotherapy ndcated for noperable, nonmetastatc non-small-cell lung cancer. Proc ASCO abstract No., 99 (2) DILLMAN RO, SEAGREN SL, PROPERT KJ, ET AL: A randomzed tral of nducton chemotherapy plus hgh-dose radaton versus radaton alone n stage III non-small-cell lung cancer. N Engl J Med 2: , 990 (2) WHITE JE, CHEN T, REED R, ET AL: Lmted squamous cell carcnoma of the lung: A Southwest Oncology Group randomzed study of radaton wth or wthout doxorubcn chemotherapy and wth or wthout levamsole mmunotherapy. Cancer Treat Rep :-20, 92 (2) MATTSON K, HOLSTI LR, HOLSTI P, ET AL: Inoperable non-small-cell lung cancer Radaton wth or wthout chemotherapy. Eur J Cancer Cln Oncol :4-42, 9 (29) MOUNTAIN CF: A new nternatonal stagng system for lung cancer. Chest 9:22-2, 9 (0) SHUM KY, KRIS MG, GRALLA RJ, ET AL: Phase II study of -ethyl-- deaza-amnoptern (-EDAM) n patents wth stage III and IV nonsmall-cell lung cancer. J Cln Oncol :44-^0,9 () DEPERRE A, LEMARIE E, DABOUIS G, ET AL: Effcacy of Navelbne (NVB) n non-small-cell lung cancer. Semn Oncol :2-29, 99 (2) GRALLA RJ: Preoperatve and adjuvant chemotherapy n non-small-cell lung cancer. Semn Oncol (Suppl ):-2, 9 () PUJOL JL, ROSSI JF, LE CHEVALIER T, ET AL: Neoadjuvant chemotherapy n stage IIIA non-small-cell lung cancer (CLC) wth csplatnum, fosfamde and etoposde. Proc ASCO 9:2, 990 Downloaded from at Pennsylvana State Unversty on May, Journal of the Natonal Cancer Insttute
7 (4) VOICES EE, BITRAN JD, HOFFMAN PC, ET AL: Neoadjuvant vndesne, etoposde and csplatn for locally advanced non-small-cell lung cancer. Chest 9:-, 99 () THAMES HD, HENDRY JM: Fractonaton n Radotherapy. London: Taylor and Francs, 9 () SCHAAXE-KONING C, BATERUNK H: Radotherapy and csdammne dchloroplatnum as a combned treatment modalty n patents wth noperable non-small-cell lung cancer A randomzed phase II study. Lung Cancer 4:A, 9 () SORESI E, CLERICI M, GRILU R, ET AL: A randomzed clncal tral comparng radaton therapy versus radaton therapy plus cs-dchjorodammne platnum (II) n the treatment of locally advanced non small-cell lung cancer. Semn Oncol :20-2, 9 Appendx The followng centers (prncpal nvestgators) partcpated n ths study: Insttut Gustave-Roussy, Vllejuf (R. Arragada, T. Le Chevaler, P. Ruffle); Centre Medtco-Chrurgcal de la Porte de Chosy, Pars (P. Baldeyrou); Centre Hosptaler Intercommunal, Cretel (H. de Cremoux, M. Martn, I. Monnet); Centre Hosptaler Regonal, Strasbourg (E. Quox); Centre Ren Gauducheau, Nantes (J.Y. Doullard); Fondaton Bergone, Bordeaux (P. Chomy); Hptal Antone Beclere, Clamart (M.L. Cerrna); Centre Hosptaler, Compegne (M.P. Challet); Centre Francos Baclesse, Caen (A. Rvere); Centre Paul Papn, Angers (C. Tuchas); Centre Hosptalo-Unverstare, Bchat (D. Belpomme); Centre Antone Lacassagne, Nce (J.L. Lagrange); Centre Hosptalo-Unverstare La Pt-Salptrere (B. Dautzenberg); Centre Hosptaler, Lorent (Y. Dumesnl); Cabnet de Pneumologe, Clermont-Ferrand (A. Tourreau); Centre Hosptaler, Troyes (P. Meekel); Centre Hosptaler, Corbel (J. Huet, J.C. Saltel); Centre Hosptaler, Beauvas (F. Ozanne); Centre Alexs Vautrn, Nancy (I. Krakowsk); Insttuto Portuguese de Oncologa Francsco Gentl, Lsbonne (M. Vlhena); Centre Hosptaler, Sant-Quentn (Tran Ngoc Quang); Centre de Physotherape du Rouget, Sarcelles (A. Kanou); Centre Hosptaler General Robert Ballanger, Aulnay-sous-Bos (M. Matheu); and Centre Hosptaler, La Roche-sur-Yon (J. Guevenoux). Alternatng Hepatc Intra-Arteral Floxurdne and Fluorouracl: A Less Toxc Regmen for Treatment of Lver Metastases From Colorectal Cancer Robert J. Stagg, Alan P. Venook* Judy L. Chase, Bran J. Lews, Robert S. Warren, Mark Roh, Sean J. Mulvhll, Barry J. Grobman, Anthony A. Rayner, Davd C. Hohn Hepatc ntra-arteral (HIA) nfuson of floxurdne (FUDR) va an mplanted pump has shown promse n the treatment of colorectal cancer metastaszed to the lver. However, the potental beneft of ths therapy may be offset by the hgh ncdence of treatment-lmtng blary toxcty. Although weekly HIA bolus of fluorouracl (-FU) s effectve aganst metastatc colorectal cancer to the lver wth no blary toxcty, t s lmted by systemc sde effects. In December 9, we began a phase II tral of alternatng HIA FUDR and -FU va the mplanted pump n an attempt to extend the duraton of treatment by obvatng the lmtng blary (FUDR) and systemc (-FU) drug toxc effects. Patents receved contnuous HIA FUDR at 0. mg/kg of body weght per day on days through followed by an HIA bolus of - FU at mg/kg gven va the pump sdeport on days, 22, and 29, wth the cycle repeated every days. Sxty-eght patents were enrolled n ths tral, and 4 were fully evaluable. Of the 4 patents, 0 (4%) prevously had receved chemotherapy. Major response (complete response plus partal response) was observed n 2 (0%) of 4 patents, and the medan survval from pump mplantaton n all patents was 22.4 months. In contrast to the experence wth the sngle-agent HIA FUDR regmen, no patent had treatment termnated because of drug toxcty. Alternatng HIA FUDR and -FU has effcacy smlar to that of HIA FUDR gven alone, but when closely montored and adjusted approprately, s not assocated wth toxc effects requrng treatment termnaton. [J Natl Cancer Inst :42-42, 99] Colorectal cancer s the thrd most common cancer n the Unted States, wth about newly dagnosed cases per year (/). About one half of all these patents ultmately wll develop metastatc spread to the lver, and n one half of those, lver nvolvement wll be the domnant clncal problem (2J). Receved August, 990; revsed December, 990; accepted December, 990. R. J. Stagg, A. P. Venook, B. J. Grobman, Cancer Research Insttute, Unversty of Calforna, San Francsco, Calf. J. L. Chase, Department of Pharmacy, M. D. Anderson Cancer Center, Houston, Tex. B. J. Lews, Department of Oncology, Kaser Permanente Medcal Center, San Francsco, Calf. R. S. Warren, S. J. Mulvhll, Department of Surgery, Unversty of Calforna, San Francsco. M. Roh, D. C. Hohn, Department of Surgery, M. D. Anderson Cancer Center. A. A. Rayner, Department of Surgery, Kaser Permanente Medcal Center, San Francsco. *Correspondence to: Alan P. Venook, MD, Cancer Research Insttute, M- 22/02, Unversty of Calforna, San Francsco, CA 944. Downloaded from at Pennsylvana State Unversty on May, 20 Vol., No., March 20,99 ARTICLES 42
Giuseppe Cartel, Francesco Cartel, Aldo Cantone, Domenico Causarano, Giuseppe Genco, Arnaldo Tobaldin, Gaetano Interlandi, Tullio Giraldi*
CsplatnCyclophosphamdeMtomycn Combnaton Chemotherapy Wth Supportve Care Versus Supportve Care Alone for Treatment of Metastatc NonSmallCell Lung Cancer Guseppe Cartel, Francesco Cartel, Aldo Cantone, Domenco
More informationLarynx Preservation in Pyriform Sinus Cancer: Preliminary Results of a European Organization for Research and Treatment of Cancer Phase III Trial
Larynx Preservaton n Pyrform Snus Cancer: Prelmnary Results of a European Organzaton for Research and Treatment of Cancer Phase Tral JeanLous Lefebvre, Domnque Chevaler, Bernard Lubonsk, Anne Krkpatrck,
More informationTHE NATURAL HISTORY AND THE EFFECT OF PIVMECILLINAM IN LOWER URINARY TRACT INFECTION.
MET9401 SE 10May 2000 Page 13 of 154 2 SYNOPSS MET9401 SE THE NATURAL HSTORY AND THE EFFECT OF PVMECLLNAM N LOWER URNARY TRACT NFECTON. L A study of the natural hstory and the treatment effect wth pvmecllnam
More informationPANCREATIC CANCER. - Exocrine: the production of enzymes that help digesting fats and proteins.
PANCREATIC CANCER 1. The pancreas It s a 15 cm gland located between the stomach and the spne, ntmately related to the vascular structures. It s dvded nto 3 parts: the wder end s called head, the mddle
More informationNational Polyp Study data: evidence for regression of adenomas
5 Natonal Polyp Study data: evdence for regresson of adenomas 78 Chapter 5 Abstract Objectves The data of the Natonal Polyp Study, a large longtudnal study on survellance of adenoma patents, s used for
More informationTHE IMPACT OF IMPLANTABLE CARDIOVERTER- DEFIBRILLATORS ON MORTALITY AMONG PATIENTS ON THE WAITING LIST FOR HEART TRANSPLANTATION
THE IMPACT OF IMPLANTABLE CARDIOVERTER- DEFIBRILLATORS ON MORTALITY AMONG PATIENTS ON THE WAITING LIST FOR HEART TRANSPLANTATION Implantable cardoverter-defbrllators were nvestgated for ther mpact on mortalty
More informationCancer morbidity in ulcerative colitis
Gut, 982, 2, 49-497 Cancer morbdty n ulceratve colts P PRIOR, S N GYDE, J C ACARNEY, H HOPSON, J A H WAERHOUSE, and R N ALLAN rom the Gastroenterology Unt, General Hosptal, Brmngham, and Cancer Epdemology
More information(From the Gastroenterology Division, Cornell University Medical College, New York 10021)
ROLE OF HEPATIC ANION-BINDING PROTEIN IN BROMSULPHTHALEIN CONJUGATION* BY N. KAPLOWITZ, I. W. PERC -ROBB,~ ANn N. B. JAVITT (From the Gastroenterology Dvson, Cornell Unversty Medcal College, New York 10021)
More informationModeling the Survival of Retrospective Clinical Data from Prostate Cancer Patients in Komfo Anokye Teaching Hospital, Ghana
Internatonal Journal of Appled Scence and Technology Vol. 5, No. 6; December 2015 Modelng the Survval of Retrospectve Clncal Data from Prostate Cancer Patents n Komfo Anokye Teachng Hosptal, Ghana Asedu-Addo,
More informationRENAL FUNCTION AND ACE INHIBITORS IN RENAL ARTERY STENOSISA/adbon et al. 651
Downloaded from http://ahajournals.org by on January, 209 RENAL FUNCTION AND INHIBITORS IN RENAL ARTERY STENOSISA/adbon et al. 65 Downloaded from http://ahajournals.org by on January, 209 Patents and Methods
More informationParameter Estimates of a Random Regression Test Day Model for First Three Lactation Somatic Cell Scores
Parameter Estmates of a Random Regresson Test Day Model for Frst Three actaton Somatc Cell Scores Z. u, F. Renhardt and R. Reents Unted Datasystems for Anmal Producton (VIT), Hedeweg 1, D-27280 Verden,
More informationRecent Trends in U.S. Breast Cancer Incidence, Survival, and Mortality Rates
Recent Trends n U.S. Breast Cancer Incdence, Survval, and Mortalty Rates Kenneth C. Chu, Robert E. Tarone, Larry G. Kessler, Lynn A. G. Res, Benjamn F. Hankey, Banj A. Mller, Brenda K. Edwards* Background:
More informationLeukemia in Polycythemia Vera. Relationship to Splenic Myeloid Metaplasia and Therapeutic Radiation Dose
Leukema n Polycythema Vera Relatonshp to Splenc Myelod Metaplasa and Therapeutc Radaton Dose JOHN H. LAWRENCE, M.D., D.SC, F.A.C.P., H. S. WINCHELL, M.D., PH.D., F.A.CP., and W. G. DONALD, M.D., F.A.C.P.
More informationJoint Modelling Approaches in diabetes research. Francisco Gude Clinical Epidemiology Unit, Hospital Clínico Universitario de Santiago
Jont Modellng Approaches n dabetes research Clncal Epdemology Unt, Hosptal Clínco Unverstaro de Santago Outlne 1 Dabetes 2 Our research 3 Some applcatons Dabetes melltus Is a serous lfe-long health condton
More informationDECREASING SYMPTOMS IN INTERSTITIAL CYSTITIS PATIENTS: PENTOSAN POLYSULFATE VS. SACRAL NEUROMODULATION. A Research Project by. Katy D.
DECREASING SYMPTOMS IN INTERSTITIAL CYSTITIS PATIENTS: PENTOSAN POLYSULFATE VS. SACRAL NEUROMODULATION. A Research Project by Katy D. Prce Bachelor of General Studes, Unversty of Kansas, 2005 Submtted
More informationCopy Number Variation Methods and Data
Copy Number Varaton Methods and Data Copy number varaton (CNV) Reference Sequence ACCTGCAATGAT TAAGCCCGGG TTGCAACGTTAGGCA Populaton ACCTGCAATGAT TAAGCCCGGG TTGCAACGTTAGGCA ACCTGCAATGAT TTGCAACGTTAGGCA
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repostory of the Radboud Unversty Njmegen The followng full text s a publsher's verson. For addtonal nformaton about ths publcaton clck ths lnk. http://hdl.handle.net/2066/23963
More informationCarcinoembryonic antigen in patients with intraeranial tumors
J Neurosurg 53:355-360, 980 Carcnoembryonc antgen n patents wth ntraeranal tumors YASUO SUZUKI, M.D., AND RvuIfm TANAKA, M.D. Department of Neurosurgery, Bran Research Insttute, Ngata Unversty, Ngata,
More informationNHS Outcomes Framework
NHS Outcomes Framework Doman 1 Preventng people from dyng prematurely Indcator Specfcatons Verson: 1.21 Date: May 2018 Author: Clncal Indcators Team NHS Outcomes Framework: Doman 1 Preventng people from
More informationConcentration of teicoplanin in the serum of adults with end stage chronic renal failure undergoing treatment for infection
Journal of Antmcrobal Chemotherapy (1996) 37, 117-121 Concentraton of tecoplann n the serum of adults wth end stage chronc renal falure undergong treatment for nfecton A. MercateUo'*, K. Jaber*, D. Hfflare-Buys*,
More informationAlma Mater Studiorum Università di Bologna DOTTORATO DI RICERCA IN METODOLOGIA STATISTICA PER LA RICERCA SCIENTIFICA
Alma Mater Studorum Unverstà d Bologna DOTTORATO DI RICERCA IN METODOLOGIA STATISTICA PER LA RICERCA SCIENTIFICA Cclo XXVII Settore Concorsuale d afferenza: 13/D1 Settore Scentfco dscplnare: SECS-S/02
More informationTHIS IS AN OFFICIAL NH DHHS HEALTH ALERT
THIS IS AN OFFICIAL NH DHHS HEALTH ALERT Dstrbuted by the NH Health Alert Network Health.Alert@dhhs.nh.gov August 26, 2016 1430 EDT (2:30 PM EDT) NH-HAN 20160826 Recommendatons for Accurate Dagnoss of
More informationRADIOLOGICAL DIFFERENTIATION BETWEEN WILM'S TUMOUR
Vol. 9, No. 3. September, 1968. SINGAPORE MEDICAL JOURNAL 161 RADIOLOGICAL DIFFERENTIATION BETWEEN WILM'S TUMOUR AND NEUROBLASTOMA IN ABDOMINAL MASSES By Yu Sheng Fong, M.B.B.S., D.M.R.D. (Rado Dagnostc
More informationSurvival Comparisons for Breast Conserving Surgery and Mastectomy Revisited: Community Experience and the Role of Radiation Therapy
Clncal Medcne & Research Volume 13, Number 2: 65-73 2015 Marshfeld Clnc Health System clnmedres.org Orgnal Research Survval Comparsons for Breast Conservng Surgery and Mastectomy Revsted: Communty Experence
More informationSaeed Ghanbari, Seyyed Mohammad Taghi Ayatollahi*, Najaf Zare
DOI:http://dx.do.org/10.7314/APJCP.2015.16.14.5655 and Anthracyclne- Breast Cancer Treatment and Survval n the Eastern Medterranean and Asa: a Meta-analyss RESEARCH ARTICLE Comparng Role of Two Chemotherapy
More information310 Int'l Conf. Par. and Dist. Proc. Tech. and Appl. PDPTA'16
310 Int'l Conf. Par. and Dst. Proc. Tech. and Appl. PDPTA'16 Akra Sasatan and Hrosh Ish Graduate School of Informaton and Telecommuncaton Engneerng, Toka Unversty, Mnato, Tokyo, Japan Abstract The end-to-end
More informationEvaluation of the generalized gamma as a tool for treatment planning optimization
Internatonal Journal of Cancer Therapy and Oncology www.jcto.org Evaluaton of the generalzed gamma as a tool for treatment plannng optmzaton Emmanoul I Petrou 1,, Ganesh Narayanasamy 3, Eleftheros Lavdas
More informationSERUM TUMOR MARKERS FOR DETECTION OF BONE METASTASIS IN BREAST CANCER PATIENTS
Acta Oncologcu Vol. 33, No. 2, pp. 181-186, 1994 SERUM TUMOR MARKERS FOR DETECTON OF BONE METASTASS N BREAST CANCER PATENTS ADNAN AYDNER, ERKAN Topuz, RAN D~q, VLDAN YASASEVER, MAKTAV D~NCER, KORAY DNCoL
More informationThe effect of salvage therapy on survival in a longitudinal study with treatment by indication
Research Artcle Receved 28 October 2009, Accepted 8 June 2010 Publshed onlne 30 August 2010 n Wley Onlne Lbrary (wleyonlnelbrary.com) DOI: 10.1002/sm.4017 The effect of salvage therapy on survval n a longtudnal
More informationUsing the Perpendicular Distance to the Nearest Fracture as a Proxy for Conventional Fracture Spacing Measures
Usng the Perpendcular Dstance to the Nearest Fracture as a Proxy for Conventonal Fracture Spacng Measures Erc B. Nven and Clayton V. Deutsch Dscrete fracture network smulaton ams to reproduce dstrbutons
More informationWHO S ASSESSMENT OF HEALTH CARE INDUSTRY PERFORMANCE: RATING THE RANKINGS
WHO S ASSESSMENT OF HEALTH CARE INDUSTRY PERFORMANCE: RATING THE RANKINGS ELLIOTT PARKER and JEANNE WENDEL * Department of Economcs, Unversty of Nevada, Reno, NV, USA SUMMARY Ths paper examnes the econometrc
More informationEstimation of Relative Survival Based on Cancer Registry Data
Revew of Bonformatcs and Bometrcs (RBB) Volume 2 Issue 4, December 203 www.sepub.org/rbb Estmaton of Relatve Based on Cancer Regstry Data Olaf Schoffer *, Ante Nedostate 2, Stefane J. Klug,2 Cancer Epdemology,
More informationPrediction of Total Pressure Drop in Stenotic Coronary Arteries with Their Geometric Parameters
Tenth Internatonal Conference on Computatonal Flud Dynamcs (ICCFD10), Barcelona, Span, July 9-13, 2018 ICCFD10-227 Predcton of Total Pressure Drop n Stenotc Coronary Arteres wth Ther Geometrc Parameters
More informationNatural History of Bronchopleural Fistula After Pneumonectomy: A Review of 96 Cases
Natural Hstory of Bronchopleural Fstula After Pneumonectomy: A Revew of 96 Cases Peter H. Hollaus, MD, Franz Lax, MD, PhD, Basem B. EI-Nashef, MD, Herwg H. Hauck, MD, Paolo Luccarn, MD, and Nestor S. Prdun,
More informationLateral Transfer Data Report. Principal Investigator: Andrea Baptiste, MA, OT, CIE Co-Investigator: Kay Steadman, MA, OTR, CHSP. Executive Summary:
Samar tmed c ali ndus t r esi nc 55Fl em ngdr ve, Un t#9 Cambr dge, ON. N1T2A9 T el. 18886582206 Ema l. nf o@s amar t r ol l boar d. c om www. s amar t r ol l boar d. c om Lateral Transfer Data Report
More informationPrice linkages in value chains: methodology
Prce lnkages n value chans: methodology Prof. Trond Bjorndal, CEMARE. Unversty of Portsmouth, UK. and Prof. José Fernández-Polanco Unversty of Cantabra, Span. FAO INFOSAMAK Tangers, Morocco 14 March 2012
More informationInternational Journal of Emerging Technologies in Computational and Applied Sciences (IJETCAS)
Internatonal Assocaton of Scentfc Innovaton and Research (IASIR (An Assocaton Unfyng the Scences, Engneerng, and Appled Research Internatonal Journal of Emergng Technologes n Computatonal and Appled Scences
More informationEncoding processes, in memory scanning tasks
vlemory & Cognton 1976,4 (5), 501 506 Encodng processes, n memory scannng tasks JEFFREY O. MILLER and ROBERT G. PACHELLA Unversty of Mchgan, Ann Arbor, Mchgan 48101, Three experments are presented that
More informationPhysical Model for the Evolution of the Genetic Code
Physcal Model for the Evoluton of the Genetc Code Tatsuro Yamashta Osamu Narkyo Department of Physcs, Kyushu Unversty, Fukuoka 8-856, Japan Abstract We propose a physcal model to descrbe the mechansms
More informationEconomic crisis and follow-up of the conditions that define metabolic syndrome in a cohort of Catalonia,
Economc crss and follow-up of the condtons that defne metabolc syndrome n a cohort of Catalona, 2005-2012 Laa Maynou 1,2,3, Joan Gl 4, Gabrel Coll-de-Tuero 5,2, Ton Mora 6, Carme Saurna 1,2, Anton Scras
More informationDecreased Nailfold Capillary Density in Limited Scleroderma with Pulmonary Hypertension. and a longer disease duration. 3,4
j :1.1 4 1, t j f ASAN PACFC JOURNAL OF ALLERGY AND MMUNOLOGY (1998) 16: 81-86 Decreased Nalfold Capllary Densty n Lmted Scleroderma wth Pulmonary Hypertenson t r Yang Y. Ong, Tony Nkoloutsopoulos, Coln
More informationEffect of Acute-Phase Retinopathy of Prematurity on Grating Acuity Development in the Very Low Birth Weight Infant
Effect of Acute-Phase Retnopathy of Prematurty on Gratng Acuty Development n the Very Low Brth Weght Infant Velma Dobson* Graham E. Qurng C. Gal Summers,X Rchard A. Saunders,\ Dale L. Phelps,\\ Betty Tung,^
More informationModeling Multi Layer Feed-forward Neural. Network Model on the Influence of Hypertension. and Diabetes Mellitus on Family History of
Appled Mathematcal Scences, Vol. 7, 2013, no. 41, 2047-2053 HIKARI Ltd, www.m-hkar.com Modelng Mult Layer Feed-forward Neural Network Model on the Influence of Hypertenson and Dabetes Melltus on Famly
More informationLength of Hospital Stay After Acute Myocardial Infarction in the Myocardial Infarction Triage and Intervention (MITI) Project Registry
JACC Vol. 28, No. 2 287 CLINICAL STUDIES MYOCARDIAL INFARCTION Length of Hosptal Stay After Acute Myocardal Infarcton n the Myocardal Infarcton Trage and Interventon (MITI) Project Regstry NATHAN R. EVERY,
More informationStatistical models for predicting number of involved nodes in breast cancer patients
Vol.2, No.7, 641-651 (2010) do:10.4236/health.2010.27098 Health Statstcal models for predctng number of nvolved nodes n breast cancer patents Alok Kumar Dwved 1 *, Sada Nand Dwved 2, Suryanarayana Deo
More informationThe Effect of Fish Farmers Association on Technical Efficiency: An Application of Propensity Score Matching Analysis
The Effect of Fsh Farmers Assocaton on Techncal Effcency: An Applcaton of Propensty Score Matchng Analyss Onumah E. E, Esslfe F. L, and Asumng-Brempong, S 15 th July, 2016 Background and Motvaton Outlne
More informationST Segment Tracking for Rapid Determination of Patency of the Infarct-Related Artery in Acute Myocardial Infarction
JACC Vol. 26, No. 3 675 ST Segment Trackng for Rapd Determnaton of Patency of the nfarct-related Artery n Acute Myocardal nfarcton ALAND R. FERNANDEZ, MD, RAFAEL F. SEQUERA, MD, FRCP, FACC, SMON CHAKKO,
More information( ) Outline. Internal Dosimetry for Targeted Radionuclide Therapy. Glenn Flux. Initial uses of TRT: I-131 NaI therapy for Ca Thyroid
Outlne Internal Dosmetry for Targeted Radonuclde Therapy Glenn Flux Royal Marsden Hosptal & Insttute of Cancer Research Surrey, UK Background to targeted radonuclde therapy (TRT) MIRD methodology Whole-body
More informationStudies In Blood Preservation
Howard Unversty Dgtal Howard @ Howard Unversty Faculty Reprnts 12-1-1939 Studes In Blood Preservaton Charles R. Drew Follow ths and addtonal works at: http://dh.howard.edu/reprnts Part of the Medcne and
More informationNormal variation in the length of the luteal phase of the menstrual cycle: identification of the short luteal phase
Brtsh Journal of Obstetrcs and Gvnaecologjl July 1984, Vol. 9 1, pp. 685-689 Normal varaton n the length of the luteal phase of the menstrual cycle: dentfcaton of the short luteal phase ELIZABETH A. LENTON,
More informationSequential meta-analysis to determine whether or not to start another trial: the high frequency versus conventional mechanical ventilation example
. Sequental meta-analyss to determne whether or not to start another tral: the hgh frequency versus conventonal mechancal ventlaton example Sequental analyss shows value of new trals Casper W. Bollen,
More informationBalanced Query Methods for Improving OCR-Based Retrieval
Balanced Query Methods for Improvng OCR-Based Retreval Kareem Darwsh Electrcal and Computer Engneerng Dept. Unversty of Maryland, College Park College Park, MD 20742 kareem@glue.umd.edu Douglas W. Oard
More informationALMALAUREA WORKING PAPERS no. 9
Snce 1994 Inter-Unversty Consortum Connectng Unverstes, the Labour Market and Professonals AlmaLaurea Workng Papers ISSN 2239-9453 ALMALAUREA WORKING PAPERS no. 9 September 211 Propensty Score Methods
More informationHIV/AIDS-related Expectations and Risky Sexual Behavior in Malawi
Unversty of Pennsylvana ScholarlyCommons PSC Workng Paper Seres 7-29-20 HIV/AIDS-related Expectatons and Rsky Sexual Behavor n Malaw Adelne Delavande RAND Corporaton, Nova School of Busness and Economcs
More informationWhat Determines Attitude Improvements? Does Religiosity Help?
Internatonal Journal of Busness and Socal Scence Vol. 4 No. 9; August 2013 What Determnes Atttude Improvements? Does Relgosty Help? Madhu S. Mohanty Calforna State Unversty-Los Angeles Los Angeles, 5151
More informationJournal of Engineering Science and Technology Review 11 (2) (2018) Research Article
Jestr Journal of Engneerng Scence and Technology Revew () (08) 5 - Research Artcle Prognoss Evaluaton of Ovaran Granulosa Cell Tumor Based on Co-forest ntellgence Model Xn Lao Xn Zheng Juan Zou Mn Feng
More informationWe analyze the effect of tumor repopulation on optimal dose delivery in radiation therapy. We are primarily
INFORMS Journal on Computng Vol. 27, No. 4, Fall 215, pp. 788 83 ISSN 191-9856 (prnt) ó ISSN 1526-5528 (onlne) http://dx.do.org/1.1287/joc.215.659 215 INFORMS Optmzaton of Radaton Therapy Fractonaton Schedules
More informationHIV/AIDS-related Expectations and Risky Sexual Behavior in Malawi
HIV/AIDS-related Expectatons and Rsky Sexual Behavor n Malaw Adelne Delavande Unversty of Essex and RAND Corporaton Hans-Peter Kohler Unversty of Pennsylvanna January 202 Abstract We use probablstc expectatons
More informationSurvival Rate of Patients of Ovarian Cancer: Rough Set Approach
Internatonal OEN ACCESS Journal Of Modern Engneerng esearch (IJME) Survval ate of atents of Ovaran Cancer: ough Set Approach Kamn Agrawal 1, ragat Jan 1 Department of Appled Mathematcs, IET, Indore, Inda
More informationThe impact of asthma self-management education programs on the health outcomes: A meta-analysis (systemic review) of randomized controlled trials
Calforna State Unversty, San Bernardno CSUSB ScholarWorks Theses Dgtzaton Project John M. Pfau Lbrary 2003 The mpact of asthma self-management educaton programs on the health outcomes: A meta-analyss (systemc
More informationUsing Past Queries for Resource Selection in Distributed Information Retrieval
Purdue Unversty Purdue e-pubs Department of Computer Scence Techncal Reports Department of Computer Scence 2011 Usng Past Queres for Resource Selecton n Dstrbuted Informaton Retreval Sulleyman Cetntas
More informationStatistical Analysis on Infectious Diseases in Dubai, UAE
Internatonal Journal of Preventve Medcne Research Vol. 1, No. 4, 015, pp. 60-66 http://www.ascence.org/journal/jpmr Statstcal Analyss on Infectous Dseases 1995-013 n Duba, UAE Khams F. G. 1, Hussan H.
More informationEffect of mannitol on cerebral blood flow and cerebral perfusion pressure in human head injury
J Neurosurg 63:43-48, 1985 Effect of manntol on cerebral blood flow and cerebral perfuson pressure n human head njury A. DAVD MENDELOW, PH.D., F.R.C.S., GRAHAM M. TEASDALE, M.R.C.P., F.R.C.S., THOMAS RUSSELL,
More informationImpact of Imputation of Missing Data on Estimation of Survival Rates: An Example in Breast Cancer
Orgnal Artcle Impact of Imputaton of Mssng Data on Estmaton of Survval Rates: An Example n Breast Cancer Banesh MR 1, Tale AR 2 Abstract Background: Multfactoral regresson models are frequently used n
More informationDS May 31,2012 Commissioner, Development. Services Department SPA June 7,2012
. h,oshawa o Report To: From: Subject: Development Servces Commttee Item: Date of Report: DS-12-189 May 31,2012 Commssoner, Development Fle: Date of Meetng: Servces Department SPA-2010-09 June 7,2012 Applcaton
More informationOptimal Planning of Charging Station for Phased Electric Vehicle *
Energy and Power Engneerng, 2013, 5, 1393-1397 do:10.4236/epe.2013.54b264 Publshed Onlne July 2013 (http://www.scrp.org/ournal/epe) Optmal Plannng of Chargng Staton for Phased Electrc Vehcle * Yang Gao,
More informationEFFECT OF TOPICAL LIGNOCAINE ON THE SYMPATHODRENAL RESPONSES TO TRACHEAL INTUBATION
Br. J. Anaesth. (1987), 59, 300-304 EFFECT OF TOPICAL LIGNOCAINE ON THE SYMPATHODRENAL RESPONSES TO TRACHEAL INTUBATION D. R. DERBYSHIRE, G. SMITH AND K. J. ACHOLA Hypertenson and tachycarda assocated
More informationRECENT STUDIES in this department
Preventon of Coronary Atheroscleross by -Androgen Admnstraton n the Cholesterol-Fed Chck By JEREMAH STAMLER, M.D., RUTH PCK, M.D., AND LOUS X. KATZ, M.D. s are hghly effectve both prophylacteally and therapeutcally
More informationNon-parametric Survival Analysis for Breast Cancer Using nonmedical
IOSR Journal Of Humantes And Socal Scence (IOSR-JHSS) Volume 1, Issue 5, Ver. 1 (May. 16) PP -34 e-issn: 79-837, p-issn: 79-845. www.osrjournals.org Non-parametrc Survval Analyss for Breast Cancer Usng
More informationTIME RESPONSE OF JEJUNAL SUCRASE AND MALTASE ACTIVITY TO A HIGH SUCROSE DIET IN NORMAL MAN
GASTROEKTEROLOGY Copyrght 1969 by The Wllams & Wlkns Co. Vol. 56, No.3 Prnted n U.S.A. TIME RESPONSE OF JEJUNAL SUCRASE AND MALTASE ACTIVITY TO A HIGH SUCROSE DIET IN NORMAL MAN NORTON S. RoSENSWEIG, M.D.,
More informationDrug Prescription Behavior and Decision Support Systems
Drug Prescrpton Behavor and Decson Support Systems ABSTRACT Adverse drug events plague the outcomes of health care servces. In ths research, we propose a clncal learnng model that ncorporates the use of
More informationAppendix for. Institutions and Behavior: Experimental Evidence on the Effects of Democracy
Appendx for Insttutons and Behavor: Expermental Evdence on the Effects of Democrac 1. Instructons 1.1 Orgnal sessons Welcome You are about to partcpate n a stud on decson-makng, and ou wll be pad for our
More informationMyocardial Mural Thickness During the Cardiac Cycle
Myocardal Mural Thckness Durng the Cardac Cycle By Erc O. Fegl, M.D., and Donald L. Fry, M.D. An understandng of the relatonshp between forces and veloctes of contracton n muscle fbers to the pressures
More informationThallium Redistribution in Dogs with Severe Coronary Artery Stenosis of Fixed Caliber
Thallum Redstrbuton n Dogs wth Severe Coronary Artery Stenoss of Fxed Calber 439 GERALD M. POHOST, ROBERT D. OKADA, DENNIS D. O'KEEFE, HENRY GEWIRTZ, GEORGE BELLER, H. WILLIAM STRAUSS, JOHN S. CHAFFIN,
More informationA GEOGRAPHICAL AND STATISTICAL ANALYSIS OF LEUKEMIA DEATHS RELATING TO NUCLEAR POWER PLANTS. Whitney Thompson, Sarah McGinnis, Darius McDaniel,
A GEOGRAPHICAL AD STATISTICAL AALYSIS OF LEUKEMIA DEATHS RELATIG TO UCLEAR POWER PLATS Whtney Thompson, Sarah McGnns, Darus McDanel, Jean Sexton, Rebecca Pettt, Sarah Anderson, Monca Jackson ABSTRACT:
More informationINITIAL ANALYSIS OF AWS-OBSERVED TEMPERATURE
INITIAL ANALYSIS OF AWS-OBSERVED TEMPERATURE Wang Yng, Lu Xaonng, Ren Zhhua, Natonal Meteorologcal Informaton Center, Bejng, Chna Tel.:+86 684755, E-mal:cdcsjk@cma.gov.cn Abstract From, n Chna meteorologcal
More informationNon-linear Multiple-Cue Judgment Tasks
Non-lnear Multple-Cue Tasks Anna-Carn Olsson (anna-carn.olsson@psy.umu.se) Department of Psychology, Umeå Unversty SE-09 87, Umeå, Sweden Tommy Enqvst (tommy.enqvst@psyk.uu.se) Department of Psychology,
More informationThe High way code. the guide to safer, more enjoyable drug use. (alcohol)
The Hgh way code the gude to safer, more enjoyable drug use (alcohol) ntroducng the GDS Hgh Way Code GDS knows pleasure drves drug use, not the avodance of harm. As far as we know no gude has ever outlned
More informationGurprit Grover and Dulumoni Das* Department of Statistics, Faculty of Mathematical Sciences, University of Delhi, Delhi, India.
Journal of AIDS and HIV Research Vol. 3(), pp. -9, January 20 Avalable onlne http:// academcjournals.org/jahr ISSN 24-2359 20 Academc Journals Full Length Research Paper Decrement table and the estmaton
More informationStrategies for the Early Diagnosis of Acute Myocardial Infarction Using Biochemical Markers
Clncal Chemstry / EARLY DIAGNOSIS OF ACUTE MYOCARDIAL INFARCTION USING IOCHEMICAL MARKERS Strateges for the Early Dagnoss of Acute Myocardal Infarcton Usng ochemcal Markers Martna Zannotto, Leopoldo Celegon,
More informationIncorrect Beliefs. Overconfidence. Types of Overconfidence. Outline. Overprecision 4/22/2015. Econ 1820: Behavioral Economics Mark Dean Spring 2015
Incorrect Belefs Overconfdence Econ 1820: Behavoral Economcs Mark Dean Sprng 2015 In objectve EU we assumed that everyone agreed on what the probabltes of dfferent events were In subjectve expected utlty
More informationA Meta-Analysis of the Effect of Education on Social Capital
A Meta-Analyss of the Effect of Educaton on Socal Captal Huang Jan ** "Scholar" Research Center for Educaton and Labor Market Department of Economcs, Unversty of Amsterdam and Tnbergen Insttute by Henrëtte
More informationSystematic review and meta-analysis Tropical Medicine Nov, 4 th 2016
Systematc revew and meta-analyss Tropcal Medcne Nov, 4 th 2016 Ammarn Thakknstan, Ph.D. Secton for Clncal Epdemology and Bostatstcs Faculty of Medcne, Ramathbod Hosptal e-mal: ammarn.tha@mahdol.ac.th www.ceb-rama.org
More informationPSI Tuberculosis Health Impact Estimation Model. Warren Stevens and David Jeffries Research & Metrics, Population Services International
PSI Tuberculoss Health Impact Estmaton Model Warren Stevens and Davd Jeffres Research & Metrcs, Populaton Servces Internatonal June 2009 Ths document may be freely revewed, quoted, reproduced or translated,
More informationNBER WORKING PAPER SERIES THE IMPACT OF HEALTH INSURANCE EXPANSION ON PHYSICIAN TREATMENT CHOICE: MEDICARE PART D AND PHYSICIAN PRESCRIBING
NBER WORKING PAPER SERIES THE IMPACT OF HEALTH INSURANCE EXPANSION ON PHYSICIAN TREATMENT CHOICE: MEDICARE PART D AND PHYSICIAN PRESCRIBING Tanyan Hu Sandra L. Decker Shn-Y Chou Workng Paper 20708 http://www.nber.org/papers/w20708
More informationInvestigation of zinc oxide thin film by spectroscopic ellipsometry
VNU Journal of Scence, Mathematcs - Physcs 24 (2008) 16-23 Investgaton of znc oxde thn flm by spectroscopc ellpsometry Nguyen Nang Dnh 1, Tran Quang Trung 2, Le Khac Bnh 2, Nguyen Dang Khoa 2, Vo Th Ma
More informationJournal of Economic Behavior & Organization
Journal of Economc Behavor & Organzaton 133 (2017) 52 73 Contents lsts avalable at ScenceDrect Journal of Economc Behavor & Organzaton j ourna l ho me pa g e: www.elsever.com/locate/jebo Perceptons, ntentons,
More informationCT scans (Computed Tomography) Information for patients Radiology
CT scans (Computed Tomography) Informaton for patents Radology page 2 of 16 What s a CT scan? CT s a short way of sayng Computed Tomography. Computer Tomography scannng s used commonly n the dagnoss of
More informationRHEUMATOID ARTHRITIS PATIENTS CANNOT ACCURATELY REPORT SIGNS OF INFLAMMATORY ACTIVITY
Brtsh Journal of Rheumatology 995;4:547-55 RHEUMATOID ARTHRITIS PATIENTS CANNOT ACCURATELY REPORT SIGNS OF INFLAMMATORY ACTIVITY S. E. HEWLETT, J. HAYNES, L. SHEPSTONE and J. R. KIRWAN Unversty of Brstol
More informationExperimental Study of Dielectric Properties of Human Lung Tissue in Vitro
Journal of Medcal and Bologcal Engneerng, 34(6): 598-64 598 Expermental Study of Delectrc Propertes of Human Lung Tssue n Vtro Je-Ran Wang 1 Ben-Yuan Sun 1 Hua-Xang Wang 1,* Shan Pang 1 Xao Xu Qng Sun
More informationVALIDATION TOOL THE SETTING OF THE COMMUNITY PHARMACY
#VT01-1 VALIDATION TOOL THE SETTING OF THE COMMUNITY PHARMACY The pharmacy settng can alter the qualty of patent care and may nfluence patent satsfacton. An approprate settng may ncrease the probablty
More informationNATIONAL QUALITY FORUM
NATIONAL QUALITY FORUM NQF #1551 Measure Evaluaton 4.1 December 2009 Ths form contans the measure nformaton submtted by stewards. Blank felds ndcate no nformaton was provded. Attachments also may have
More informationKOUJI KAJINAMI, MD,*t HIROYASU SEKI, MD,t NOBORU TAKEKOSHI, MD,t HIROSHI MABUCHI, MD* Kanazawa, Japan
JACC Vol. 26, No. 5 209 November I, 995:209-2 Nonnvasve Predcton of Coronary Atheroscleross by Quantfcaton of Coronary Artery Calcfcaton Usng Electron Beam Computed Tomography: Comparson Wth Electrocardographc
More informationSingle-Case Designs and Clinical Biofeedback Experimentation
Bofeedback and Self-Regulaton, VoL 2, No. 3, 1977 Sngle-Case Desgns and Clncal Bofeedback Expermentaton Davd H. Barow: Brown Unversty and Butler Hosptal Edward B. Blanchard Unversty of Tennessee Medcal
More information1 0 1 Neither A nor B I Both Anti-A and Anti-B 1 0, A, B, AB I 0 1. Simulated ABO 6; Rh Bood vping Lab Activity Student Study Guide BACKGROUND
Smulated ABO 6; Rh Bood vpng Lab Actvty Student Study Gude BACKGROUND nces Around 900, Karl Landstener dscovered that there are at least four dfferent knds of human blood, determned by the presence or
More informationGASTROINTESTINAL MOTILITY AND GASTRIC ph AND EMPTYING FOLLOWING INGESTION OF DIAZEPAM
Br. J. Anaesth. (1988), 61, 712-719 GASTROINTESTINAL MOTILITY AND GASTRIC ph AND EMPTYING FOLLOWING INGESTION OF DIAZEPAM B. A. SCHURIZEK, K. KRAGLUND, F. ANDREASEN, L. V. JENSEN AND B. JUHL Premedcaton
More informationThis article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and
Ths artcle appeared n a journal publshed by Elsever. The attached copy s furnshed to the author for nternal non-commercal research and educaton use, ncludng for nstructon at the authors nsttuton and sharng
More informationEXAMINATION OF THE DENSITY OF SEMEN AND ANALYSIS OF SPERM CELL MOVEMENT. 1. INTRODUCTION
JOURNAL OF MEDICAL INFORMATICS & TECHNOLOGIES Vol.3/00, ISSN 64-6037 Łukasz WITKOWSKI * mage enhancement, mage analyss, semen, sperm cell, cell moblty EXAMINATION OF THE DENSITY OF SEMEN AND ANALYSIS OF
More informationDeposited on: 8 May 2008 Glasgow eprints Service
Assenburg C. and Bravo-Vergel Y. and Palmer S. and Fenwck E. and de Belder M. and Abrams K.R. and Sculpher M. (2007) Assessng the effectveness of prmary angoplasty compared wth thrombolyss and ts relatonshp
More informationDisablement and Quality of Life After Stroke
886 Dsablement and Qualty of Lfe After Stroke BERIT AHLSIO, MONA BRITTON, M.D., VERONICA MURRAY, M.D., AND TORES THEORELL, M.D.* SUMMARY Ths study concerns the qualty of lfe of patents after stroke and
More information